News
CEMI
0.6311
-2.91%
-0.0189
Chembio to self-distribute COVID test in US; offer HIV test via online platform in UK, Brazil
Chembio Diagnostics (NASDAQ:CEMI) said it launched its direct-to-consumer commercial channel for InBios International's SCoV-2 Ag Detect Self-Test in the U.S. The company said the assay is a rapid immunoassay test for
Seekingalpha · 06/15 13:33
BRIEF-Chembio Diagnostics Announces Expansion Of Direct-To-Consumer Commercial Channel
reuters.com · 06/15 12:08
Chembio Diagnostics Announces Expansion Of Direct-to-Consumer Commercial Channel
Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the launch of its direct-to-consumer commercial channel for the
Benzinga · 06/15 12:04
Chembio Diagnostics Launches Commercial Channel for COVID-19 Test; Shares Rise Pre-Bell
MT Newswires · 06/15 08:59
Chembio Diagnostics's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, Chembio Diagnostics's (NASDAQ:CEMI) reported sales totaled $18.82 million. Despite a 37.09% increase in earnings, the company posted a loss of $8.79 million.
Benzinga · 05/31 13:48
BRIEF-Chembio Diagnostics Announces Election Of Leslie Teso-Lichtman To Its Board Of Directors
reuters.com · 05/24 21:25
Chembio's inks contract for HIV test to be made by Reszon Diagnostics at Malaysia facility
Chembio Diagnostics (NASDAQ:CEMI) signed an agreement under which Reszon Diagnostics International will manufacture its HIV 1/2 STAT-PAK Assay products in the Chembio Diagnostics Malaysia facility, which had previously suspended operations in May
Seekingalpha · 05/17 13:47
BRIEF-Chembio Diagnostics Announces Agreement For Reszon Diagnostics To Manufacture Chembio's HIV 1/2 STAT-PAK Assay At Co's Malaysia Facility
reuters.com · 05/17 12:13
Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia Facility
HAUPPAUGE, N.Y., May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has entered into a manufacturing agreement with Reszon Diagn...
GlobeNewswire · 05/17 12:00
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Benzinga · 05/16 09:23
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.
Benzinga · 05/09 10:27
Chembio Diagnostics GAAP EPS of -$0.29 misses by $0.08, revenue of $18.82M beats by $7.02M
Chembio Diagnostics press release (NASDAQ:CEMI): Q1 GAAP EPS of -$0.29 misses by $0.08. Revenue of $18.82M (+115.8% Y/Y) beats by $7.02M.
Seekingalpha · 05/05 20:19
-- Earnings Flash (CEMI) CHEMBIO DIAGNOSTICS Posts Q1 Loss $-0.29, vs. Street Est of $-0.21
MT Newswires · 05/05 17:12
-- Earnings Flash (CEMI) CHEMBIO DIAGNOSTICS Reports Q1 Revenue $18.8M, vs. Street Est of $11.8M
MT Newswires · 05/05 17:08
Chembio Diagnostics to Report First Quarter 2022 Financial Results on May 5, 2022
HAUPPAUGE, N.Y., April 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2022 a...
GlobeNewswire · 04/21 20:05
Looking Into Chembio Diagnostics's Return On Capital Employed
Chembio Diagnostics (NASDAQ:CEMI) brought in sales totaling $20.57 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 119.5%, resulting in a loss of $13.97 million.
Benzinga · 03/09 15:25
68 Biggest Movers From Friday
Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares jumped 101.8% to close at $40.77 on Friday after jumping 39% on Thursday.
Benzinga · 03/07 09:49
Despite More Than Double Q4 Sales, Chembio Diagnostics Posts Deeper Losses
Benzinga · 03/04 14:26
Why Chembio Diagnostics Shares Are Falling
Chembio Diagnostics Inc (NASDAQ: CEMI) shares are trading lower by 12.4% at $0.81 after the company reported worse-than-expected fourth-quarter adjusted EPS results.
Benzinga · 03/04 14:09
More
Webull provides a variety of real-time CEMI stock news. You can receive the latest news about Chembio Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CEMI
Chembio Diagnostics, Inc. develops and commercializes point-of-care diagnostic tests used for the rapid detection and diagnosis of infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19, and other viral and bacterial infections, enabling expedited treatment. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs, and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections (STIs) and human immunodeficiency virus (HIV), gastroenterology, and women's health. Its products include COVID-19 Antibody Test System, COVID-19 Antigen Test System, COVID-19 and Influenza Respiratory Antigen Panel Test System and HIV-Syphilis Diagnostic Test Systems, among others. It is also targeting lateral flow test solutions for infectious diseases.